Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Phase 1/2 Completed 42 enrolled University of California, Davis National Cancer Institute (NCI) · collab

Non-randomizedCrossoverOpen-labelTreatment

Summary

RATIONALE: Pemetrexed disodium and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pemetrexed disodium together with erlotinib may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of pemetrexed disodium and erlotinib and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.

Timeline

Start: 2005-03
Primary completion: 2007-10
Completion: 2009-05

Publications

Results Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul;4(7):862-8. doi: 10.1097/JTO.0b013e3181a94b08.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	—	Oral
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Summary

Timeline

Publications

Drugs

Indications